Accéder au contenu
Merck

Effect of butaclamol, a new neuroleptic, on serotoninergic mechanisms.

The Journal of pharmacy and pharmacology (1977-03-01)
T A Pugsley, W Lippmann
PMID15075
RÉSUMÉ

Butaclamol (1.0-0.1 mg kg-1, i.p.) and spiroperidol (1-0-0-5 mg kg-1, i.p.) but not (-)-butaclamol (15 mg kg-1, i.p.), blocked the hyperactivity induced in rats by tranylcypromine-L-tryptophan pretreatment. Neither butaclamol nor spiroperidol altered the accumulation of brain 5-HT following parglyine or the decline of brain 5-HT following inhibition with the tryptophan hydroxylase inhibitor alpha-propyldopacetamide thus indicating that butaclamol and spiroperidol do not affect either the synthesis or the turnover of brain 5-HT. It is concluded that the antagonism of the tranylcypromise-L-tryptophan-induced hyperactivity by butaclamol and spiroperidol is due to their blockade of dopaminergic receptors rather than an action on neuronal serotoninergic mechanisms.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
(−)-Butaclamol hydrochloride, solid